We are live on
!
Find out more
CBIO
Crescent Biopharma
CBIO
CBIO
63 hedge funds and large institutions have $477M invested in Crescent Biopharma in 2026 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 18 increasing their positions, 8 reducing their positions, and 11 closing their positions.
New
Increased
Maintained
Reduced
Closed
125% more repeat investments, than reductions
Existing positions increased: 18 | Existing positions reduced: 8
100% more funds holding in top 10
Funds holding in top 10: 2 → 4 (+2)
67% more capital invested
Capital invested by funds: $286M → $477M (+$191M)
55% more first-time investments, than exits
New positions opened: 17 | Existing positions closed: 11
9% more funds holding
Funds holding: 58 → 63 (+5)
79.42% less ownership
Funds ownership: 173.59% → 94.17% (-79%)
Holders
63
Holders Change
+5
Holders Change %
+8.62%
% of All Funds
0.78%
Holding in Top 10
4
Holding in Top 10 Change
+2
Holding in Top 10 Change %
+100%
% of All Funds
0.05%
New
17
Increased
18
Reduced
8
Closed
11
Calls
–
Puts
–
Net Calls
–
Net Calls Change
–
Top Buyers
| 1 |
Balyasny Asset Management
Chicago,
Illinois
|
+$16.1M |
| 2 |
TCM
Tang Capital Management
San Diego,
California
|
+$3.3M |
| 3 |
Millennium Management
New York
|
+$3M |
| 4 |
Goldman Sachs
New York
|
+$2.33M |
| 5 |
Marshall Wace
London,
United Kingdom
|
+$2.05M |
